Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

Core Viewpoint - Recursion Pharmaceuticals is positioned for significant growth due to its innovative technology and drug development methods, although it currently lacks marketed products and relies on collaborations for revenue [1][3]. Company Overview - Recursion Pharmaceuticals has a market capitalization of approximately $2.2 billion and generated trailing-12-month revenue of $46.2 million solely from collaborations with larger biopharmaceutical companies [3]. - The company has several programs in its pipeline aimed at treating rare diseases, with three in phase 2 trials and additional oncology programs [3]. Revenue Generation Potential - The company could generate revenue through new collaborations or by expanding existing ones, leveraging its AI-driven drug discovery platform to reduce costs and improve efficiency [4][5]. - Recursion could potentially earn up to $2.3 billion in milestone payments from current agreements, averaging about $230 million per year over the next decade, not including royalties or sales from in-house developed medicines [8]. Drug Development Outlook - Assuming successful drug launches, particularly from its phase 2 programs, the company could see total revenue of approximately $3 billion over the next 10 years, averaging $300 million per year [10]. - The expected sales from its therapies, primarily targeting rare diseases, may not reach blockbuster status but could still yield around $700 million over seven years [10]. Market Capitalization Projections - With an annual revenue of $300 million and a current price-to-sales (P/S) ratio of 39.6, the market capitalization could rise to about $118 billion, representing a 5,164% increase from its current value [11]. Investment Considerations - An initial investment of $19,400 could potentially grow to over $1 million under ideal conditions, although such a large upfront investment may not be feasible for most investors [12]. - The investment outlook remains speculative, as the company may not achieve all milestone payments and its drug sales could be significantly lower than projected [14].

Company Overview - Recursion Pharmaceuticals (RXRX) ended the recent trading session at $8.19, showing a -1.92% change from the previous day's closing price, which is less than the S&P 500's daily gain of 0.08% [1] - The upcoming earnings release is projected to report earnings of -$0.35 per share, representing year-over-year growth of 7.89%, with revenue estimated at $14.09 million, up 27.82% from the year-ago period [5] Financial Performance - The Zacks Consensus Estimates forecast earnings of -$1.56 per share and revenue of $47.44 million for the entire year, indicating changes of +1.27% and +6.43%, respectively, compared to the previous year [2] - Prior to today's trading, shares of Recursion Pharmaceuticals had gained 11.33% over the past month, outperforming the Medical sector's gain of 0.48% and the S&P 500's loss of 0.21% during the same period [8] Analyst Ratings - Recursion Pharmaceuticals currently holds a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate moving 2.66% higher within the past month [3] - The Zacks Rank system has a history of outperforming, with 1 stocks returning an average annual gain of +25% since 1988 [3] Industry Context - The Medical - Drugs industry, which includes Recursion Pharmaceuticals, has a Zacks Industry Rank of 97, placing it in the top 39% of all 250+ industries [10] - The Zacks Industry Rank assesses the strength of specific industry groups, showing that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

There's a lot to like about the company using automation and artificial intelligence to improve the new drugdiscovery process. Recursion Pharmaceuticals (RXRX 3.73%) is a start-up biotech company with an important twist. It's using automation technology and artificial intelligence (AI) to industrialize new drug discovery. Why Recursion Pharmaceuticals looks like a good investment New drug candidates discovered by Recursion should also have a better chance at success in clinical trials because there's a lot ...

Core Viewpoint - Recursion Pharmaceuticals is positioned at the forefront of a potential paradigm shift in drug discovery through its AI-driven approach, but it faces significant challenges and competition that may hinder its success [2][3][5]. Company Overview - Recursion Pharmaceuticals utilizes an AI algorithm to test clinical compounds against a library of human genes, aiming to enhance the probability of success from pre-clinical testing to regulatory approval [3]. - The company currently has no products on the market or in late-stage studies, which raises concerns about its approach and increases the risk associated with its stock [4][5]. Competitive Landscape - The biotech industry is witnessing increased competition, particularly from established players like Novo Nordisk, which is developing an AI supercomputer to enhance drug research and development [8][13]. - Novo Nordisk's extensive data from its drug development history and greater financial resources present a formidable challenge to Recursion Pharmaceuticals [8][14]. Development Challenges - The drug development process is inherently difficult, with many candidates failing at various stages, including pre-clinical and multiple phases of human trials [10]. - Recursion Pharmaceuticals has approximately six programs in clinical trials, most of which are in phase 2, which is not particularly impressive for a clinical-stage biotech [12]. Future Potential - If Recursion Pharmaceuticals can successfully navigate the competitive landscape and demonstrate tangible results from its AI-driven platform, it could see substantial upside potential in its stock [11][15]. - The company may benefit from a network effect as its AI algorithm learns from successes and failures, although there is currently no data to support this development [15].

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. About Recursion Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a pric ...

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. About Recursion Forward-Looking Statements Investor Contact: media@recursion.com Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public of ...

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area, and London. Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $9.38, reflecting a +0.43% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. Elsewhere, the Dow saw a downswing of 0.1%, while the tech-heavy Nasdaq appreciated by 0.16%. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.60 per share and revenue of $45.99 million. These totals would mark changes of - ...

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, anal ...